T‐cell‐rich B‐cell lymphoma – diagnostic and therapeutic aspects
T‐cell‐rich B‐cell lymphoma – diagnostic and therapeutic aspects
复制标题
富含 T 细胞的 B 细胞淋巴瘤 – 诊断和治疗方面
DOI：
--
复制
发表时间：
2002
期刊：
影响因子：
--
通讯作者：
M. Bjorkholm
中科院分区：
文献类型：
--
作者：
U. Axdorph;A. Porwit‐Macdonald;J. Sjoberg;G. Grimfors;M. Bjorkholm
背景形态学上，富含T细胞的B细胞淋巴瘤（TCR B-NHL）可能无法与霍奇金病（HD）区分。免疫分型可能有助于这些实体的分离。TCRB-NHL偶尔会被误诊为HD。然而，关于该患者人群的临床特征和结局的信息有限。此外，关于TCR B-NHL中与Epstein巴尔病毒（EBV）的任何相关性，以及反应性T细胞的免疫表型和T细胞胞内抗原-1（TIA-1）、颗粒酶B（GrB）和CD 3-β-链的表达的知识有限。患者和方法。我们重新评价了1985-1994年诊断为HD的≥15岁患者的251例肿瘤活检。12例病例（5%）从HD重新分类为TCRB-NHL。还纳入了最初诊断为B-NHL并接受治疗的6例TCR B-NHL患者。对所有TCRB-NHL活检组织进行了潜伏膜蛋白1（LMP-1）、CD 4、CD 8、CD 56、CD 57、TIA-1、GrB和CD 3-β-链分析。结果12例TCRB-NHL病例最初被细分为HD（淋巴细胞优势5例，结节硬化3例，混合细胞4例）。在这12例TCRB-NHL患者中，6例仅接受放疗，5例接受MOPP/ABVD或类似联合化疗，1例接受联合治疗。接受HD治疗的TCRB-NHL患者（n=12）与其余确诊（conf）HD患者相比，男性（p<0.05）和腹股沟受累（p<0.001）的发生率显著更高，而在分期、骨髓浸润、脾肿大或病因特异性生存率方面未见显著差异。当所有TCRB-NHL患者（n=18）与conf HD患者进行比较时，获得了相似的结果。三份样本中的淋巴瘤细胞LMP-1染色呈阳性。在9/14例肿瘤活检中观察到CD 3-β-链表达降低。结论免疫组织化学使识别TCRB-NHL病例成为可能，这些病例在形态学上难以与HD区分。接受HD治疗的TCRB-NHL患者的结局与其余HD人群的结局相当。
Background. Morphologically, T‐cell‐rich B‐cell lymphoma (TCRB‐NHL) may be indistinguishable from Hodgkin's disease (HD). Immunophenotyping may be helpful in the separation of these entities. TCRB‐NHL is occasionally misdiagnosed and treated as HD. However, information is limited regarding clinical characteristics and outcome of this patient population. Furthermore, knowledge concerning any association with Epstein‐Barr virus (EBV) in TCRB‐NHL, as well as the immunophenotype of reactive T‐cells and the expression of T‐cell intracellular antigen‐1 (TIA‐1), granzyme B (GrB) and the CD3‐ζ‐chain is limited. Patients and methods. We have re‐evaluated 251 tumour biopsies from patients aged ≥15 years with HD diagnosed 1985–1994. Reclassification from HD to TCRB‐NHL was done in 12 cases (5%). Six TCRB‐NHL patients initially diagnosed and treated as B‐NHL were also included. All TCRB‐NHL biopsies were analysed for latent membrane protein 1 (LMP‐1), CD4, CD8, CD56, CD57, TIA‐1, GrB and CD3‐ζ‐chain. Results. Twelve cases of TCRB‐NHL were initially subclassified as HD (lymphocyte predominance 5, nodular sclerosis 3, and mixed cellularity 4). Of these 12 TCRB‐NHL patients, 6 were given radiotherapy alone, 5 MOPP/ABVD or similar combination chemotherapy, and one patient combined modality treatment. Male sex (p<0.05) and inguinal involvement (p<0.001) were significantly more frequent when TCRB‐NHL patients receiving HD treatment (n=12) were compared with the remaining patients with confirmed (conf) HD, while no significant differences were seen with regard to stage, bone marrow infiltration, splenomegaly or cause‐specific survival. Similar results were achieved when all TCRB‐NHL patients (n=18) were compared to conf HD patients. Lymphoma cells in three samples stained positively for LMP‐1. A decreased expression of CD3‐ζ‐chain was seen in 9/14 tumour biopsies. Conclusion. Immunohistochemistry makes it possible to identify cases of TCRB‐NHL that are morphologically difficult to distinguish from HD. The outcome of TCRB‐NHL patients treated as having HD was comparable with that of the remaining HD population.
影响因子：
11.2
作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
通讯作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
周围 T 细胞淋巴瘤并发大 B 细胞增殖。
DOI：
10.1309/72cm-kaxf-66de-4xva
发表时间：
2000
期刊：
American journal of clinical pathology.
影响因子：
--
作者：
Higgins,JP;vandeRijn,M;Jones,CD;Zehnder,JL;Warnke,RA
通讯作者：
Warnke,RA
肿瘤部位 T 细胞中 zeta 链的缺失或低表达与口腔癌患者的生存率较低有关。
影响因子：
11.2
作者：
Reichert,TE;Day,R;Wagner,EM;Whiteside,TL
通讯作者：
Whiteside,TL